Trial Profile
Phase 1/2 Study of DSP-7888 in Patients With Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Adegramotide/nelatimotide (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 01 Apr 2022 Results published in the Cancer Science
- 18 Dec 2020 Status changed from active, no longer recruiting to completed.
- 08 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 Mar 2020.